Executive Summary
Women referred for primary mitral regurgitation intervention die sooner than men — a JACC: Cardiovascular Imaging meta-analysis of 25,690 patients pegs the survival deficit at 5.8 months over 15.7 years, with older age at referral and untreated concomitant tricuspid regurgitation doing most of the damage. The finding lands directly on the ESC 2025 upgrade to Class I early repair in asymptomatic PMR with multiple risk features, and it argues that current LV- and LA-based thresholds are systematically referring women too late. On the aortic side, a 262-patient TAVR cohort followed 7.6 years found 40.5% all-cause mortality and confirmed malnutrition matters (log-rank p<0.001) but that GNRI, PNI, and CONUT scores are not independent predictors. CMS has reopened its national coverage analysis on TAVR — the first structural review since 2019 — which complicates the case for expanding TAVR to lower-risk and moderate-AS populations in the US.
- Female sex confers 15% higher all-cause mortality after PMR intervention (HR 1.15, 95% CI 1.07-1.24), with concomitant TR the strongest moderator (JACC: Cardiovascular Imaging).
- Supra-annular TAVR valve deterioration tracks with annular size and residual gradient in a new JACC: Asia analysis — a durability signal that matters for the sub-70 cohort.
- CMS opened NCA CAG-00430R, revisiting the 2019 TAVR coverage framework.
- Nutritional risk scores (GNRI, PNI, CONUT) fail as independent mortality predictors in a 262-patient TAVR series despite 79.8% GNRI-defined malnutrition (BMC Cardiovascular Disorders).
- Kauvery Hospital reports a first-in-world simultaneous transcatheter treatment of two failing heart valves in one patient (ANI News).
What to watch: the CMS public comment window on TAVR NCA CAG-00430R. The shape of any revised coverage determination will define whether US practice tracks the ESC 2025 age-70 threshold or holds to the ACC/AHA 2020 framework.
Aortic Valve (TAVR/TAVI)
Two aortic signals today, both pushing back on the "TAVR everywhere" narrative. The JACC: Asia analysis of valve deterioration after supra-annular TAVR ties SVD to annular size and residual gradient — the mechanism is intuitive (small annulus, high gradient, more leaflet stress), but the data confirm that anatomy at the index procedure drives durability, not device generation alone. ACC/AHA 2020 favors SAVR up to age 65 and shared decision-making from 65-80 specifically because surgical bioprostheses carry 15-20 year durability data that TAVR cannot yet match. This matters directly for the ESC 2025 shift lowering the TAVR-preferred threshold to age 70: patients in the 70-80 window are exactly those for whom a 10-year durability question is clinical, not theoretical. The 262-patient Turkish TAVR cohort (retrospective, single-center, 7.6-year follow-up, 40.5% mortality) tested three nutritional indices and none survived multivariable adjustment — a useful negative result that pushes back on enthusiasm for pre-TAVR nutritional risk stratification. Malnutrition matters; these scores aren't the tool.
[NOTABLE] CMS has formally reopened the TAVR NCA (CAG-00430R) — the first national coverage review since 2019, before the low-risk trials matured and before EARLY TAVR. The current NCD requires two cardiac surgeons for candidacy assessment, minimum institutional volumes, and STS/ACC TVT registry participation. Every element is now in play. Expect industry advocacy to push for loosened volume thresholds and expanded coverage to moderate AS; expect the surgical societies to defend the two-surgeon requirement and volume floors. The clinical evidence base has shifted substantially since 2019, but so has the durability question in younger patients. This is the single most consequential US structural heart regulatory action of the year.
Mitral Valve (MitraClip, PASCAL, TMVR)
[NOTABLE] Women die sooner after PMR intervention, and the drivers are late referral and undertreated tricuspid disease — not LV or LA remodeling. The JACC: Cardiovascular Imaging meta-analysis pooled 17 studies and 25,690 patients, reconstructing individual patient time-to-event data. Women were 37.5% of the cohort, referred 3.2 years older, with 1.8-fold higher heart failure symptoms at presentation. At 15.7 years follow-up, female sex carried HR 1.15 (95% CI 1.07-1.24) for all-cause mortality and HR 1.37 (1.11-1.70) for MACE. The moderators define the story: age, moderate-or-greater TR, and concomitant TV repair were significant (all p≤0.03), while LV and LA parameters were not. The ESC 2025 upgrade to Class I for early MV repair in asymptomatic PMR when three of four risk features are present (AF, SPAP >50, LAVI ≥60 or LA ≥55mm, moderate-or-greater TR) directly addresses part of this — moderate TR is now an explicit trigger, not a downstream complication. ACC/AHA 2020 remains at Class IIa and requires >95% repair success and <1% mortality at reference centers, a bar that delays referral in practice. This meta-analysis is the strongest evidence to date that the ACC/AHA threshold is calibrated to the male phenotype, and that guideline updates need sex-specific trigger criteria — particularly around the decision to add concomitant tricuspid repair. Limitations are real: observational studies throughout, heterogeneous surgical and TEER cohorts pooled, and 15.7-year follow-up spanning multiple technique eras.
Tricuspid Valve (TriClip, TTVR)
No dedicated tricuspid trial data today, but the mitral meta-analysis carries direct tricuspid implications: undertreated concomitant TR at the time of PMR intervention drives excess female mortality. The ESC 2025 upgrade of TV surgery for symptomatic severe primary TR to Class I, and concomitant TV repair during left-sided surgery for moderate TR with annular dilation to Class I, directly addresses this signal. ACC/AHA 2020 sits one class lower on both. The JACC: Cardiovascular Imaging finding that concomitant TVr was a moderator of higher female mortality is more nuanced than it first reads — it likely reflects that women who require TVr at the time of MV intervention are already further advanced in disease, not that the tricuspid intervention itself is harmful. This is the too-late-referral problem in a different guise, and it applies with equal force to isolated tricuspid intervention. Transcatheter TR options (EVOQUE, TriClip) sit at ESC Class IIa, LOE A; ACC/AHA 2020 has no formal recommendation — the next US update is expected to move.
Surgical vs. Transcatheter Comparisons
No head-to-head data today. The PMR meta-analysis is dominated by surgical cohorts (sensitivity analysis HR 1.18 in surgery-only studies) and does not parse TEER-vs-surgery outcomes by sex — a gap that grows in importance as TEER expands to intermediate-risk PMR. The supra-annular TAVR durability signal indirectly reinforces the surgical case in younger patients where annular anatomy is suboptimal.
Device & Technology
Kauvery Hospital Alwarpet reports the first catheter-based simultaneous treatment of two failing heart valves in a 58-year-old man. Case report, no peer-reviewed data, no long-term follow-up — treat as a proof-of-concept marker for concurrent multi-valve transcatheter workflow, not a practice signal.
Regulatory & Policy
[NOTABLE] CMS has opened NCA CAG-00430R on TAVR — the first national coverage review since 2019. The current NCD requires two cardiac surgeons for candidacy assessment, minimum institutional volumes, and STS/ACC TVT registry participation. Every element is now in play. Expect industry advocacy to push for loosening volume thresholds and expanding to moderate AS; expect the surgical societies to defend the two-surgeon requirement and volume floors. The clinical evidence base has shifted substantially since 2019 (low-risk trials, EARLY TAVR, DEDICATE) but so has the durability question in younger patients. This is the single most consequential US structural heart regulatory action of the year.
Financial Analysis
The CMS NCA is the immediate catalyst for EW. Any expansion of coverage to moderate AS or lower-volume centers is TAM-accretive; any tightening around durability data or volume thresholds is the reverse. EW's 11% six-month gain likely already prices in optimism about the review outcome. Boston Scientific's 53% six-month decline is a separate story tied to broader medtech multiple compression and legacy business concerns, not structural heart specifically — the WATCHMAN and TEER franchises remain intact. Abbott's 24% decline sits in the middle. Anteris continues its 95% six-month run, though thin trading volume (10,218 shares) means the mark is fragile.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $92.21, +0.96% on the day; 6-month +11.08%
- Market cap $53.1B; trailing P/E 49.84, forward 27.38; beta 0.85
- 52-week range $72.30 - $96.29 — trading near the top
- Consensus target $97.92 (26 analysts, buy)
- Next earnings 2026-07-23, EPS est $0.74, revenue est $1.70B
The CMS TAVR NCA is the near-term swing factor. Q2 print will parse SAPIEN growth against PASCAL and EVOQUE ramp; watch for any commentary on moderate-AS strategy in the earnings call.
Medtronic (MDT)
- Close: $83.87, +1.80% on the day; 6-month -12.00%
- Market cap $107.4B; trailing P/E 22.49, forward 13.09; beta 0.58
- 52-week range $73.31 - $106.33
- Consensus target $97.00 (26 analysts, buy)
- Next earnings 2026-08-18, EPS est $1.39, revenue est $9.55B
Evolut positioning under a CMS review favors self-expanding platforms for challenging anatomies. Structural is a smaller piece of the MDT story than for EW; the drag has been diabetes and broader portfolio.
Abbott (ABT)
- Close: $93.93, -0.50% on the day; 6-month -23.78%
- Market cap $163.6B; trailing P/E 26.31, forward 15.51; beta 0.61
- 52-week range $81.97 - $137.49
- Consensus target $116.40 (25 analysts, buy)
- Next earnings 2026-07-16, EPS est $1.28, revenue est $12.52B
TriClip and Navitor are the structural heart storylines. The mitral sex-differences meta-analysis is a longer-term tailwind for TEER expansion if guidelines push earlier referral in women.
Boston Scientific (BSX)
- Close: $44.77, -0.49% on the day; 6-month -53.23%
- Market cap $66.5B; trailing P/E 18.73, forward 12.07; beta 0.58
- 52-week range $42.25 - $109.50
- Consensus target $73.86 (29 analysts, strong buy)
- Next earnings 2026-07-29, EPS est $0.83, revenue est $5.37B
Trading at 52-week lows with a strong-buy consensus and a $73.86 target — the disconnect is stark. ACURATE neo2 remains commercially available in Europe but pulled from the US after ACURATE IDE. WATCHMAN and EP are the base case.
Anteris Technologies (AVR.AX)
- Close: A$13.18, -1.20% on the day; 6-month +95.26%
- Market cap A$1.3B; forward P/E -6.04 (pre-revenue); beta 0.73
- 52-week range A$4.68 - A$15.47
- Single-analyst target A$13.00
DurAVR THV pivotal trial progression drives the tape. Thin volume (10,218 shares) means the six-month double is fragile to any dilution or trial delay.
Market outlook: the CMS TAVR NCA overhangs EW and MDT specifically. Any signal on volume thresholds, moderate-AS coverage, or two-surgeon requirements will move both. The mitral sex-differences finding is a slower-moving tailwind for TEER volumes across ABT (TriClip, MitraClip) and EW (PASCAL) if guideline bodies act on it.
Clinical Trial Updates
Aortic
- NCT07696182 — VOYAGER (EncantoR software-guided TAVI validation). Status: not yet recruiting. Prospective, single-arm, multi-center, N=150. Sponsor: Abbott Medical Devices. Anatomy-specific implantation software — relevant to the supra-annular durability signal in today's JACC: Asia piece, since positioning drives residual gradient.
- NCT07566624 — Spanish Hydra THV registry. Status: recruiting. N=100. Sponsor: Fundación EPIC. Real-world Hydra data in the Spanish market.
- NCT07695701 — Acoramidis CMR/echo study. Status: not yet recruiting. Phase 4, N=150. Sponsor: Eidos/BridgeBio. ATTR-CM imaging response study — matters for the AS-plus-amyloid overlap in the octogenarian TAVR population.
No mitral, tricuspid repair, or tricuspid replacement trial updates today. Landmark trials to keep tracking: EARLY TAVR (asymptomatic AS), PROGRESS (moderate AS), REPAIR-MR (surgical repair vs TEER in PMR), TRISCEND II (transcatheter TV replacement), CLASP TR.
Next up: CMS NCA public docket entries and the EW Q2 print on July 23 will set the tone for US structural heart the rest of the summer.